Save
esh.org
Chapter 20.2 -Acute lymphoblastic leukaemia in children and adolescents
ESH eLearning, Christina Peters, 165697
Chapter 20.1 - Acute myeloid leukaemia
ESH eLearning, Giorgio Dini and Stefano Giardino, 165696
Chapter 19.12 - Aplastic anaemia and paroxysmal nocturnal haemoglobinuria
ESH eLearning, Judith Marsh, 165695
Chapter 19.11 - Autoimmune diseases
ESH eLearning, John A. Snowden, Riccardo Sacc Dominique Farge, 165694
Chapter 19.10 - Solid tumours in adults
ESH eLearning, Marco Bregni, 165693
Chapter 19.9 - HSCT for Hodgkin’s lymphoma in adults
ESH eLearning, Anna Sureda and Harry C. Schouten, 165692
Chapter 19.8 - HSCT for non-Hodgkin’s lymphoma
ESH eLearning, Harry C. Schouten and Anna Sureda, 165691
Chapter 19.7 - Role of HSCT in primary amyloidosis
ESH eLearning, M. Teresa Cibeira and Jordi Esteve, 165690
Chapter 19.6 - Multiple myeloma
ESH eLearning, Jesús San-Miguel, José A. Pére M. Victoria Mateos, 165689
Chapter 19.5 - Chronic lymphocytic leukaemia
ESH eLearning, Peter Dreger and Johannes Schetelig, 165688
Chapter 19.4 - Chronic myeloid leukaemia and the myeloproliferative disorders
ESH eLearning, Jiri Pavlu and Jane Apperley, 165687
Chapter 19.3 - HSCT for myelodysplastic syndromes
ESH eLearning, Nicolaus Kröger, 165686
Chapter 19.2 - Acute lymphoblastic leukaemia
ESH eLearning, M Mohty, 165685
Chapter 19.1 - Acute myeloid leukaemia
ESH eLearning, M Mohty, 165684
Chapter 18 - Indications for and current practice of allogeneic and autologous HSCT
ESH eLearning, Alois Gratwohl, Helen Baldomer Anna Sureda, 165683
Chapter 17 – Immunotherapy post-transplant
ESH eLearning, Inge Jedema and J.H. Frederik Falkenburg, 165682
Chapter 16.2 - Chimerism
ESH eLearning, Thomas Lion, 165681
Chapter 16.1 - Molecular monitoring of minimal residual disease
ESH eLearning, Jean-Michel Cayuela, 165680
Chapter 15 - Late effects in patients treated with HSCT
ESH eLearning, Andre Tichelli, 165679
Chapter 14 - Immune reconstitution after allogeneic HSCT
ESH eLearning, Antoine Toubert, 165678
Chapter 13 - Graft-versus-host disease
ESH eLearning, Jane Apperley and Tamas Masszi, 165677
Chapter 12 - Infections after HSCT
ESH eLearning, Montserrat Rovira, Josep Mensa Enric Carreras, 165676
Chapter 11 - Early complications after HSCT
ESH eLearning, Enric Carreras, 165675
Chapter 10 - Supportive care
ESH eLearning, Tamas Masszi and Arno Mank, 165674
Chapter 9 - Transfusion support in patients undergoing HSCT
ESH eLearning, Rachel Pawson and Derwood Pamphilon, 165673
Chapter 8 - Principles of conditioning
ESH eLearning, Alois Gratwohl and Enric Carreras, 165672
Chapter 7 - Bone marrow donor registries and cord blood banks
ESH eLearning, Carlheinz Mueller and Sergio Querol, 165671
Chapter 6 - Choice of the donor according to HLA typing and stem cell source
ESH eLearning, eliane Gluckman, 165670
Chapter 5 - Immunogenetics of allogeneic HSCT
ESH eLearning, Bronwen E. Shaw Alejandro Madrigal, 165669
Chapter 4 - Biological properties of haematopoietic stem cells
ESH eLearning, Aleksandra Wodnar-Filipowicz, 165668
Chapter 3 - JACIE & quality management in HSCT
ESH eLearning, Christian Chabannon Eoin McGrath, 165667
Chapter 2 - Present and future
ESH eLearning, Alejandro Madrigal Anna Sureda, 165666
Chapter 1 - A brief history of HSCT
ESH eLearning, eliane Gluckman, 165665
Cord blood transplant and very rare anaemias
ESH eLearning, Annalisa Ruggeri, 17976
Quality controls for the diagnosis of rare red cell disorders
ESH eLearning, Andrea Mosca, 17974
Paroxysmal Nocturnal Haemoglobinuria
ESH eLearning, Regis Peffault de Latour, 17973
Microangiopathic haemolytic anaemias - TTP, HUS ( haemolytic uraemic syndrome)
ESH eLearning, Paul Coppo, 17972
Autoimmune haemolytic anaemias by warm antibodies
ESH eLearning, Norbert Ahrens, 17970
Cold-antibody mediated autoimmune hemolytic anemia
ESH eLearning, Sigbjorn Berentsen, 17971
Clinical case 3
ESH eLearning, Joan-LLuis Vives-Corrons, 17969
Clinical case 2
ESH eLearning, A. A. M. Ermens, 19900
Clinical Case 1
ESH eLearning, R van Wijk, 19899
Normal and defective red blood cell metabolism abnormalities of glycolysis and the generation of reduced glutathione
ESH eLearning, R van Wijk, 17968
Closing talk of Day 1
ESH eLearning, Joan-LLuis Vives-Corrons, 17967
Erythropoietic porphyrias
ESH eLearning, Jean Charles Deybach, 17966
Clinical cases of membrane disorders
ESH eLearning, Alberto Zanella & Leticia Ribeiro, 19868
Hereditary elliptocytosis, pyropoikilocytosis and South-East Asian Ovalocytosis
ESH eLearning, Leticia Ribeiro, 17963
Hereditary spherocytosis
ESH eLearning, Alberto Zanella, 17962
Iron overload and chelation therapy
ESH eLearning, Maria Domenica Cappellini, 19866
Clinical cases
ESH eLearning, Maria Domenica Cappellini, 17961
Hereditary sideroblastic anaemias
ESH eLearning, Alison May, 17960
Rare inherited anaemias due to defects in the erythroblastiron acquisition pathway
ESH eLearning, Carole Beaumont, 17959
What are very rare anaemias ?
ESH eLearning, GULBIS BEATRICE, 17954
Welcome to Participants
ESH eLearning, Patricia Aguilar-Martinez, 19865
Recurrent fetal loss and thrombophilia
ESH eLearning, Saskia Middeldorp, 17339
Novel antithrombotic drugs
ESH eLearning, Sylvia Haas, 17338
Disseminated intravascular coagulation
ESH eLearning, Marcel Levi, 17337
Antiphospholipid syndrome
ESH eLearning, Ph G. de Groot, 17335
Cancer and thrombosis
ESH eLearning, Anna Falanga, 17334
Arterial thrombosis, pathogenesis, epidemiology
ESH eLearning, Gordon Lowe, 17330
Venous Thrombosis: etiology, pathogenesis and prognosis
ESH eLearning, Frits Rosendaal, 17328
Genetic risk factors of arterial and venous thrombosis
ESH eLearning, Pieter Reitsma, 17327
Control Mechanisms of coagulation
ESH eLearning, Bjorn Dahlback, 17326
Inherited platelet bleeding disorders, diagnosis and treatment
ESH eLearning, Alan Nurden, 17325
Management of coagulation disorders, complications and prevention
ESH eLearning, Pier Mannucci, 17323
Rare Bleeding Disorders
ESH eLearning, Flora Peyvandi, 17322
Molecular genetics of coagulation
ESH eLearning, Pieter Reitsma, 17320
Biochemistry of the coagulation systems
ESH eLearning, David Lane, 17319
Stopping TKI can now be recommended in selected partients: no
ESH eLearning, Giuseppe Saglio, 12583
Stopping TKI can now be recommended in selected patients: yes
ESH eLearning, François-Xavier Mahon, 12581
Debate
ESH eLearning, Session Speakers, 12606
Maintenance of a stable CCyR is an adequate therapeutic target: no
ESH eLearning, Philippe Rousselot, 12585
Maintenance of a stable CCyR is an adequate therapeutic target: yes
ESH eLearning, Michele Baccarani, 12584
All CML patients should start treatment with 2G-TKI: no
ESH eLearning, charles schiffer, 12586
Residual normal stem cells can be detected in newly diagnosed CML patients by a new flow cytometric approach and predict for optimal response to imatinib
ESH eLearning, Jeroen Janssen, 12601
The Prognostic significance of Molecular and Cytogenetic response landmarks after 3 month of Imatinib in the upfront treatment of CML
ESH eLearning, Benjamin Hanfstein, 12598
Switching to nilotinib vs imatinib dose escalation for patients with suboptimal treatment response to imatinib: 24 month update of the TIDEL-II trial
ESH eLearning, David T Yeung, 12596
High BCR-ABLIS expression levels at diagnosis and after 3 and 6 months of treatment are associated with an unfavourable response to imatinib
ESH eLearning, Paolo Vigneri, 12597
Correlation of hOCT1 genetic polymorphisms with the clinical outcome Athina Giannoudis (Liverpool) of CML patients treated with imatinib
ESH eLearning, Athina Giannoudis, 12595
BCR-ABL compound mutations in CML
ESH eLearning, Jamshid Khorashad, 12594
Debate
ESH eLearning, Session Speakers, 12604
JAK-2 is clearly an important therapeutic target in CML: no
ESH eLearning, Wolfgang Warsch, 12592
JAK-2 is clearly an important therapeutic target in CML: yes
ESH eLearning, MIN CHEN, 12590
There is a definite need to target stem cells: no
ESH eLearning, Giovanni Martinelli, 12588
CML . Reminiscences and dreams
ESH eLearning, John Goldman, 12532
Finding the soft spot: targeting CML stem cells
ESH eLearning, Mike Deininger, 12534
A novel AHI-1-BCR-ABL-JAK2 interaction complex mediates cellular resistance to tyrosine kinase inhibitors in CML stem/progenitor cells
ESH eLearning, MIN CHEN, 12535
BCL6 is required for the initiation and maintenance of CML
ESH eLearning, Christian Hurtz, 12536
Targeting of a novel MNK-eIF4E-b-catenin axis in blast crisis CML inhibits leukimia stem cell funcation
ESH eLearning, Sharon Lim, 12542
Evaluation of the efficacy and mechanism of action of the JAK2 inhibitor INCB18424 in primary CML stem/progenitor cells
ESH eLearning, Paolo Gallipoli, 12544
Keynote lecture: 10 years of imatinib resistance- heaps of mutations and a dozen new TKI : what we have learned . a biochemist.s view
ESH eLearning, Oliver Hantschet, 12558
Rac2 - mitochondrial respiratory chain complex III signaling generates reactive oxygen species causing genomic instability in CML-CP leukemia stem and progenitor cells
ESH eLearning, Piotr Kopinski, 12561
Targeting STAT5 in CML: Mechanism-of-action of JAK2 tyrosine kinase inhibitors in CML unmask a direct BCR-ABL/STAT5 axis
ESH eLearning, Wolfgang Warsch, 12562
Regulation of mature versus immature conformation of BCR-ABL
ESH eLearning, Yoshiro Maru, 12563
Man versus machine: a semi-automated platform for BCR-ABL QPCR
ESH eLearning, Jerry Radich, 12566
Distinct graft-vs-leukimic stem cell of early or delayed donor leukocyte infusions in amouse CML model
ESH eLearning, Yi-Fen Lu, 12570
The BELA trial: 18-month update on safety and clinical activity in patients with chronic phase CML treated with bosutirub (SKI-606) or imatinib
ESH eLearning, C Gambacorti, 12571
Updated phase 1 data on ponatinib, a pan-BCR-ABL inhibitor, in CML and other hematologic malignancies
ESH eLearning, Jorge Cortes, 12572
Multiple non-resistant low-level BCR-ABL1 mutations in CML patients after imatinib resitance predict poor response and high risk of new resistant mutations during the second-lin kinase inhibitor therapy
ESH eLearning, Susan Branford, 12574
A Phase 1 study of DCC-2036, an oral novel inhibitor of Abl kinase, in adult patients with Philadelphia Chromosome Positive (Ph+) CML including patients with T315I mutation
ESH eLearning, Jorge Cortes, 12578

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings